Zydus Cadila has initiated
a Phase 2 clinical trial for evaluating the effect of Saroglitazar Mg in the treatment of Non-
Alcoholic Fatty Liver Disease (NAFLD) in women with polycystic ovary syndrome (PCOS). The
EVIDENCES VII trial is currently recruiting patients across several clinical sites in the United
States of America and Mexico.
Saroglitazar Magnesium is an investigational molecule in USA, undergoing clinical evaluation for treatment of liver diseases like NAFLD with polycystic ovary syndrome (PCOS), Non-Alcoholic SteatoHepatitis (NASH) and Primary Biliary Cholangitis (PBC). Nonclinical studies have demonstrated that Saroglitazar, because of its unique mechanism of engaging PPAR alpha and PPAR gamma, favorably affects all components of NASH including steatosis, ballooning, inflammation and fibrosis.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
